NowRx

Technology-driven, on-demand pharmacy providing free, same-day delivery

Overview

Platform

SeedInvest

Start Date

01/19/2018

Close Date

06/30/2018

Min. Goal

$450,000

Max. Goal

$7,000,000

Min. Investment

$1,000

Security Type

Equity - Preferred

Funding Type

RegA+

Price Per Share

$2.00

Pre-Money Valuation

$20,000,000

Location

Mountain View, California

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

NowRx, with a valuation of $20 million, is raising funds on SeedInvest through Reg A+ crowdfunding. It is a pharmacy delivery solution that uses advanced technology to provide free same-day delivery for all prescription needs. The on-demand delivery model of NowRx offers convenience, higher worker productivity, and superior customer experience. NowRx has filled more than 16,000 prescriptions and served over 2,700 customers since June 2017, and generated revenues of approximately $1 million. Cary Breese and Sumeet Shoekand founded NowRx in 2015. The current crowdfunding campaign has a minimum target of $450,000 and a maximum target of $7,000,000. The campaign proceeds will be used for building the software, research and development, marketing, and expansion of services.

Balance Sheet

Cash and Cash Equivalents

$391,723

Accounts and Notes Receivable

$172,543

Property, Plant and Equipment (PP&E)

$136,446

Total Assets

$954,831

Accounts Payable & Accrued Liabilities

$105,609

Long Term Debt

$2,072,731

Total Liabilities

$2,188,261

Total Stockholders' Equity

$-1,233,430

Total Liabilities and Equity

$954,831

Statement of Comprehensive Income Information

Total Revenues

$994,588

Costs & Expenses Applicable to Rev

$823,073

Depreciation and Amortization

$2,677

Net Income

$-364,505

Earnings Per Share - Basic

$-0.09

Earnings Per Share - Diluted

$-0.09

Auditor: Fruci & Associates II, PLLC
Financials as of: 01/19/2018
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
NowRx 05/20/2022 SeedInvest $275,000,000 $30,006,323 Equity - Preferred Funded RegA+
NowRx 10/05/2021 SeedInvest $275,000,000 $3,635,310 Equity - Preferred Funded Test the Waters / RegA+
NowRx 06/19/2020 SeedInvest $65,000,000 $20,002,878 Equity - Preferred Funded RegA+
NowRx 06/30/2018 SeedInvest $20,000,000 $0 Equity - Preferred Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article

Summary

At time of publication, May 21, NowRX had raised $2.2M surpassing its $450K minimum

Problem

We’ve all been there. You get sick and go to the doctor, who then tells you to go and get a prescription for whatever ailment you are currently dealing with. Nothing quite like going to a CVS on the other side of town to hang out for 45 minutes while they fill your order, am I right?

Not only is the process friction filled from a customer experience standpoint, but is also a costly business to run with lots of overhead, which only helps to drive up the cost of healthcare services. In an age of on-demand everything, our pharmaceutical purchase experience should be no different.

The $260B retail RX market is in need of innovation that will help to mirror the experience customers have come to demand from e-commerce companies like Amazon. As crazy as that may sound, more-and-more C-Suite individuals from across highly regulated and slow moving industries like financial services and healthcare are speaking out on the impact that Amazon is having on customer experience demands. Customers have come to expect frictionless purchasing experiences, vast selection, and free, quick delivery no matter what the product is, be checks for a new bank account, or medicine for your sore throat.

The pharmacy industry has also been slow to innovate on ways to improve medication adherence and mistakes in medical dispensing. If we want better healthcare outcomes we will need to see more solutions like a PillPack finding unique and innovative solutions to improve both error rates and adherence.

Solution

NowRX is creating an on-demand pharmacy delivery system that is going to create cost efficiencies for the healthcare world, better service for the customer, and improved adherence to pharmaceuticals.

The solution involves creating automated drug dispensary centers that are completely automated from acceptance of the prescription to fulfillment, with free same day delivery. Customers can order through their phone via app or text to mimic services like Uber. This is enabled by the pharmacy management system the team has built on the backend to ensure accurate, compliant and friendly communications with customers. And for just $5 customers can get their medicine delivered to their door in just 1 hour.

If you think about the cost efficiencies this creates, the team touts an ability to service a geographic radius that is 5X that of a traditional drug store with its NowRX delivery service. Instead of having to build 30 or 40 CVS drug stores in a city to service customers, NowRX can build one. That type of efficiency, cost savings and improvement on customer experience is why they have been able to close agreements with McKesson, Express Scripts, Caremark and OptumRx.

It is also that efficiency that enables free same day delivery while still leaving enough margin for the company to be profitable. The fulfillment centers are extremely lean in terms of staff but the staff that is present can focus less on the manual process of finding drugs and more on ensuring quality of experience. The team is also building out its data analytics to determine ways in the future to help customers better adhere to their pharmaceutical regimens.

Once again the team is finding ways to provide value add to the healthcare system at large, which means many stakeholders, from the insurers, to the pharmaceutical organizations have a stake in seeing a business like this succeed.

Why We Like it

  1. Massive market opportunity: NowRX is innovating in the $260B retail RX market that has been dominated by old, stodgy organizations like CVS and Walgreens to date. Though there are a handful of startup competitors such as Alto, PillPack, and Caps ule innovating in this space too, there is more than enough room for several companies to win out in this space and have successful exits or IPOs.
  2. Market traction: To date, the team has only rolled out 1 center in San Francisco. With this one center the team most recently reported that ARR is at $4.3M. And the team expects each center to drive $10M in annual revenue when at full tilt. In addition during 2017, the company experienced 236% revenue growth, and since launch has serviced 5,900 customers and fulfilled 28K prescriptions.
    1. This team has shown an ability to execute on the vision successfully and with no red flags to date in the SF market.
  3. Demand for healthcare transformation: Increasingly, insurance companies which continue to raise the cost of healthcare are demanding better measures of performance to justify cost of treatments, drugs, etc. NowRX fits in perfectly with this vision because it is both more affordable, drives better adherence to drugs, and thus improves outcomes. This is something that will likely become industry standard in the years to come. That gives NowRX a strong market position early in the game.
  4. Ripe market for acquisition: Recently it was announced that PillPack is in talks with Amazon to be acquired for somewhere in the neighborhood of $1B as the organization looks to provide a uniquely differentiated offering for customers in comparison to traditional pharmacies. Amazon was also reportedly pursuing the company too as the battle to own the “e-commerce” pharmacy starts to heat up. Now RX could see some intriguing acquisition offerings in the near future.

The Leadership

Cary Brees: Co-Founder & CEO

Cary Breese is an electrical engineer who has spent the past 15+ years turning around businesses and driving huge returns for investors including at a struggling insurance business. He also led a tech company called GenieDB in a complete product and business model redirect that ended in an acquisition from a large multinational telecom organization. He also helped found a successful $50M VC fund all before starting NowRx. Needless to say Cary is extremely seasoned in building businesses, managing tight balance sheets and successfully returning investors money.

Sumeet Shoekand: Co-Founder & CTO

Sumeet Shoekand has a great deal of experience in managing product development with past management experience as Tech Manager at Experian and VP of Tech at X1 Technologies, an enterprise software company. He also has experience working with Cary, because he was the CTO at GenieDB during the turnaround efforts, which included a full product redirect.

Rating

The Recommendation:

With a pre-money valuation of $20M, and more than $4M in current ARR in just 1 west coast market that has yet to be fully penetrated, I’d say the valuation is low if anything. High growth tech companies growing over 200% YoY, can often fetch much higher valuations.

I think they are also playing in a market that is desperate for innovation and with movement from a major corporation like Amazon to acquire that tech for nearly a billion dollars bodes well for what could be coming down the pike. Building pharmacy tech is not easy and major corporations like a CVS or Amazon seem like reasonable strategic acquirers looking to create competitive offerings in this space.

With the tech lead on the robotics, automation, compliance, and the data capabilities being built, this team seems poised to have a major breakout opportunity. Cary Breese and Sumeet Shoekand are also highly seasoned, intelligent leaders who have a track record of building successful tech companies.

For those reasons I recommend NowRX as a Top Deal on the fact that they have strong leadership, terrific market traction, a defensible tech and data moat, a market ripe for disruption and the offering is well aligned with consumer trends.

Analysis written by Chris Lustrino on May 21, 2018.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
NowRx on SeedInvest 2018
$
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $20,000,000
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow NowRx on SeedInvest 2018
View on SeedInvest (Closed)